VNRX
Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
VolitionRx Limited (VNRX) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Momentum (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | B+ (3.6) | C+ (2.6) | D- (0.7) | C+ (2.6) | C+ (2.5) |
| 2026-11-08 | B- (3.0) | B+ (3.6) | C+ (2.6) | F (0.4) | C+ (2.6) | C (2.4) |
| 2026-11-01 | B- (3.0) | B+ (3.5) | C+ (2.6) | F (0.4) | C+ (2.7) | C (2.4) |
| 2026-10-25 | B- (3.0) | B+ (3.5) | C+ (2.6) | F (0.3) | C+ (2.6) | C (2.4) |
| 2026-10-18 | B- (3.0) | B+ (3.5) | C+ (2.6) | F (0.3) | C+ (2.6) | C (2.4) |